REVIEW ARTICLE |
|
Year : 2019 | Volume
: 3
| Issue : 1 | Page : 33-37 |
|
Neuromuscular-blocking agent use in critically ill patients
Shmeylan A Al Harbi1, Hind S Almodaimegh1, Yaseen M Arabi2
1 Department of Pharmaceutical Care, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia 2 Department of Intensive Care, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Correspondence Address:
Shmeylan A Al Harbi Department of Pharmaceutical Care, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2543-1854.259477
|
|
Neuromuscular-blocking agents (NMBAs) are a cornerstone in the management of critically ill patients. There is evidence supporting short course (<48 h) of paralysis for patients with moderate-to-severe acute respiratory distress syndrome with PaO2/FiO2 ratio <150. Proper knowledge of these agents and their evidence-based use is fundamental. Health-care providers can play an important role in the regulation and the use of NMBAs in critically ill patients.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|